Cardiol Therapeutics Inc. Class ATSX: CRDL

Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

Dec 16, 2022 at 5:26 PM UTC · Issued by Cardiol Therapeutics Inc. Class A

(NewsDirect)

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2022 TheNewswire - All rights reserved.

Company analysis